The US Food and Drug Administration (FDA) has accepted BeOne Medicines’ supplemental New Drug Application for Brukinsa (zanubrutinib) in combination with rituximab, granting it Priority Review. The application… read more.
Orion Pharma has announced late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2026. The data showed that adding darolutamide, an androgen receptor inhibitor (ARi)… read more.
Eli Lilly and Company announced that the FDA has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor,… read more.
Medtronic plc announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral renal denervation (RDN) system. The study showed statistically significant and clinically meaningful… read more.
Johnson & Johnson announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA (guselkumab) in… read more.
INOVIO announced that the FDA has granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with RRP…. read more.
Pfizer Inc. announced that the FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or… read more.
Pharmacy Research Showcase highlights Three routes into research At the Pharmacy Research Showcase, three people whose research is supported by Pharmacy Research UK (PRUK) described their own journeys…. read more.
Egetis Therapeutics AB announced that the FDA has approved Emcitate (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with… read more.
Olezarsen can be used as an option to treat genetically confirmed familial chylomicronaemia syndrome in adults, only if response to diet and conventional triglyceride-lowering treatments (such as statins… read more.
Shanghai Junshi Biosciences Co., Ltd. announced that the National Medical Products Administration of China has converted from conditional approval to regular approval the toripalimab injection (trade name: TUOYI,… read more.
Pharmacy Research Showcase highlights Pharmacy technicians are involved at every point in a medicine’s journey, yet they are rarely involved in research. At the Pharmacy Research Showcase, Panayiotis… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
